– USA, CA – Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, announced the appointment of Eric Chin to its Board of Directors, effective June 4, 2025, replacing Cathy Coste, who stepped down from the Board on the same date.
Eric Chin will also join the Audit Committee as Chair and the Nominating and Corporate Governance Committee, and the Compensation Committee as a member.
About Eric B. Chin
Eric Chin is an accomplished financial executive with a proven track record in healthcare and life sciences. He serves as CFO of Akido Labs, a healthcare technology company focused on preventive and data-driven care, where he successfully helped raise $60 million in a recent financing, and is a member of the Board of Directors, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation. He has also held executive roles at Astrana Health, Public Storage, and Alexandria Real Estate Equities.
Eric Chin began his career at Ernst & Young LLP and is a Certified Public Accountant.
About Biomerica
Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
For more: https://biomerica.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.